Download PDF
Semin Thromb Hemost 2004; 30(1): 5-20
DOI: 10.1055/s-2004-822967
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Contribution of the Hemostatic System to Angiogenesis in Cancer

Marek Z. Wojtukiewicz1 , 2 , Ewa Sierko2 , Janusz Rak3
  • 1Professor of Medicine and Oncology
  • 2Department of Oncology, Medical University, Bialystok, Poland
  • 3Henderson Research Centre, Experimental Thrombosis Research, McMaster University, Hamilton, Ontario, Canada
Further Information

Publication History

Publication Date:
22 March 2004 (online)

    Permissions and Reprints

It is now recognized that the hemostatic system plays an important role in cancer growth and dissemination, processes known to be vitally dependent on new tumor blood vessel formation (angiogenesis). There is also an increasing body of evidence supporting the link between the various components of the coagulation/fibrinolysis systems and angiogenic activity in cancer patients. Tissue factor (TF), thrombin, fibrinogen, fibrin, and plasminogen activation system, as well as platelets, all are able to promote angiogenesis. On the other hand, coagulation inhibitors, as well as cryptic (proteolytically released) domains of hemostatic proteins, are also known to act as angiogenesis inhibitors. Indeed, modulation (stimulation or inhibition) of angiogenesis may result from either classical functions of various molecular components of the hemostatic cascade, their less studied “alternative” activities, or both. Although much remains to be understood about this complex circuitry these considerations support the judicious use of anticoagulants in patients with malignancy as well as encourage the search for novel antiangiogenic activities that may reside within molecular and cellular components of the hemostatic system.

KEYWORDS

Hemostatic system - angiogenesis - neoplasia

REFERENCES

  • 1 Hillen H FP. Thrombosis in cancer patients.  Ann Oncol. 2000;  11(suppl 3) 273-276
    Google Scholar
  • 2 Folkman J. Tumor angiogenesis: therapeutic implications.  N Engl J Med. 1971;  285 1182-1186
    CrossrefPubMedGoogle Scholar
  • 3 Folkman J. What is the evidence that tumors are angiogenesis dependent?.  J Natl Cancer Inst. 1990;  82 4-6
    CrossrefPubMedGoogle Scholar
  • 4 Trousseau A. Phlegmasia alba dolens.  Clin Med Hôtel-Dieu Paris. 1865;  3 654-712
    PubMedGoogle Scholar
  • 5 Rickles F R, Levine M, Edwards R L. Hemostatic alterations in cancer patients.  Cancer Metastasis Rev. 1992;  11 237-248
    CrossrefPubMedGoogle Scholar
  • 6 Bick R L. Coagulation abnormalities in malignancy: a review.  Semin Thromb Hemost. 1992;  18 353-372
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Luzzato G, Schafer A I. The prethrombotic state in cancer.  Semin Oncol. 1990;  17 147-159
    PubMedGoogle Scholar
  • 8 Nand S. Hemostasis and cancer.  Cancer J. 1993;  6 54-58
    PubMedGoogle Scholar
  • 9 Donati M B. Cancer and thrombosis.  Haemostasis. 1994;  24 128-131
    PubMedGoogle Scholar
  • 10 Wojtukiewicz M Z, Zacharski L R, Memoli V A et al.. Abnormal regulation of coagulation/fibrynolysis in small cell carcinoma of the lung.  Cancer. 1990;  65 481-485
    PubMedGoogle Scholar
  • 11 Wojtukiewicz M Z, Zacharski L R, Memoli V A et al.. Fibrinogen-fibrin transformation in situ in renal cell carcinoma.  Anticancer Res. 1990;  10 579-582
    PubMedGoogle Scholar
  • 12 Wojtukiewicz M Z, Zacharski L R, Memoli V A et al.. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.  Am J Clin Pathol. 1990;  93 516-521
    PubMedGoogle Scholar
  • 13 Zacharski L R, Memoli V A, Ornstein D L, Rousseau S M, Kisiel W, Kudryk B J. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.  J Natl Cancer Inst. 1993;  85 1225-1230
    CrossrefPubMedGoogle Scholar
  • 14 Wojtukiewicz M Z, Rucinska M, Zimnoch L et al.. Expression of prothrombin fragment 1 + 2 in cancer tissue as an indicator of local activation of blood coagulation.  Thromb Res. 2000;  97 335-342
    CrossrefPubMedGoogle Scholar
  • 15 Wojtukiewicz M Z, Sierko E, Zacharski L R, Zimnoch L, Kudryk B, Kisiel W. Tissue factor dependent coagulation activation and impaired fibrinolysis in loco in gastric cancer.  Semin Thromb Hemost. 2003;  29 291-299
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Dvorak H F. Tumors: wounds that do not heal.  N Engl J Med. 1986;  315 1650-1659
    CrossrefPubMedGoogle Scholar
  • 17 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease.  Nat Med. 1995;  1 27-31
    CrossrefPubMedGoogle Scholar
  • 18 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.  Cell. 1996;  86 353-364
    CrossrefPubMedGoogle Scholar
  • 19 Carmeliet P, Jain R K. Angiogenesis in cancer and other diseases.  Nature. 2000;  407 249-257
    CrossrefPubMedGoogle Scholar
  • 20 Holash J, Maisonpierre P C, Compton D et al.. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.  Science. 1999;  284 1994-1998
    CrossrefPubMedGoogle Scholar
  • 21 Rak J, Filmus J, Kerbel R S. Reciprocal paracrine interactions between tumor cells and endothelial cells. The “angiogenesis progression” hypothesis.  Eur J Cancer. 1996;  32A 2438-2450
    PubMedGoogle Scholar
  • 22 Nicosia R F, Tchao R, Lieghton J. Angiogenesis-dependent tumor spread in reinforced fibrin clot culture.  Cancer Res. 1983;  43 2159-2166
    PubMedGoogle Scholar
  • 23 Brooks P C, Stromblad S, Klemke R, Visscher D, Sarkar F H, Cheresh D A. Anti-integrin αbβ3 blocks human breast cancer growth and angiogenesis in human skin.  J Clin Invest. 1995;  96 1815-1822
    CrossrefPubMedGoogle Scholar
  • 24 Rak J W, Hegmann E J, Lu C, Kerbel R S. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression.  J Cell Physiol. 1994;  159 245-255
    CrossrefPubMedGoogle Scholar
  • 25 Li L, Nicolson G L, Fidler I J. Direct in vitro lysis of metastatic tumor cells by cytokine-activated murine vascular endothelial cells.  Cancer Res. 1991;  51 245-254
    PubMedGoogle Scholar
  • 26 Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig N E. Halting angiogenesis suppresses carcinoma cell invasion.  Nat Med. 1997;  3 1222-1227
    CrossrefPubMedGoogle Scholar
  • 27 Hamada J, Cavanaugh P G, Miki K, Nicolson G L. A paracrine migration-stimulating factor for metastatic tumor cells secreted by mouse hepatic sinusoidal endothelial cells: identification as complement component C3b.  Cancer Res. 1993;  53 4418-4423
    PubMedGoogle Scholar
  • 28 Plate K H, Breier G, Risau G. Molecular mechanism of developmental and tumour angiogenesis.  Brain Pathol. 1994;  4 207-221
    PubMedGoogle Scholar
  • 29 Bouck N, Stellmach V, Hsu S C. How tumors become angiogenic.  Adv Cancer Res. 1996;  69 135-174
    PubMedGoogle Scholar
  • 30 Hlatky L, Tsinoru C, Hahnfeldt P, Coleman C N. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression.  Cancer Res. 1994;  54 6083-6086
    PubMedGoogle Scholar
  • 31 Fukumura D, Xavier R, Sugiura T et al.. Tumor induction of VEGF promoter activity in stromal cells.  Cell. 1998;  94 715-725
    CrossrefPubMedGoogle Scholar
  • 32 Norrby K. Mast cells and angiogenesis.  APMIS. 2002;  110 355-371
    CrossrefPubMedGoogle Scholar
  • 33 Coussens L M, Wilfred W R, Berges G et al.. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis.  Genes Dev. 1999;  13 1382-1397
    CrossrefPubMedGoogle Scholar
  • 34 Feoktistov I, Ryzhov S, Goldstein A E, Biaggioni I. Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors.  Circ Res. 2003;  92 485-492
    CrossrefPubMedGoogle Scholar
  • 35 Ohta M, Kitadai Y, Tanaka S et al.. Monocyte chemoatractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas.  Int J Oncol. 2003;  22 773-778
    PubMedGoogle Scholar
  • 36 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?.  Lancet. 2001;  357 539-545
    CrossrefPubMedGoogle Scholar
  • 37 Senger D R. Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines.  Am J Pathol. 1996;  149 1-7
    PubMedGoogle Scholar
  • 38 Pinedo H M, Verheul H MW, D'Amato R J, Folkman J. Involvement of platelets in tumor angiogenesis?.  Lancet. 1998;  352 1775-1777
    CrossrefPubMedGoogle Scholar
  • 39 Wartiovaara U, Salven P, Mikkola Heta I. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.  Thromb Haemost. 1998;  80 171-175
    PubMedGoogle Scholar
  • 40 Ferrara N. Vascular endothelial growth factor: molecular and biological aspects.  Curr Top Microbiol Immunol. 1999;  237 1-30
    PubMedGoogle Scholar
  • 41 Bikfalvi A, Klein S, Pintucci G, Rifkin D B. Biological roles of fibroblast growth factor-2.  Endocr Rev. 1997;  18 26-45
    CrossrefPubMedGoogle Scholar
  • 42 Folkman J, Shing Y. Angiogenesis.  J Biol Chem. 1992;  267 10931-10934
    PubMedGoogle Scholar
  • 43 Bussolino F, Di Renzo M F, Ziche M et al.. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.  J Cell Biol. 1992;  119 629-641
    CrossrefPubMedGoogle Scholar
  • 44 Rich J N. The role of transforming growth factor-beta in primary brain tumors.  Front Biosci. 2003;  8 e245-260
    PubMedGoogle Scholar
  • 45 Holmgren L, O'Reilly M S, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.  Nat Med. 1995;  1 149-153
    PubMedGoogle Scholar
  • 46 O'Reilly M S, Boehm T, Shing Y et al.. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.  Cell. 1997;  88 277-285
    CrossrefPubMedGoogle Scholar
  • 47 O'Reilly M S, Pirie-Shepherd S, Lane W S, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin.  Science. 1999;  285 1926-1928
    CrossrefPubMedGoogle Scholar
  • 48 Dameron K M, Volpert O V, Tainsky M A, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.  Science. 1994;  265 1582-1584
    CrossrefPubMedGoogle Scholar
  • 49 Iruela-Arispe M L, Vazquez F, Ortega M A. Antiangiogenic domains shared by thrombospondins and matallospondins, a new family of of angiogenic inhibitors.  Ann N Y Acad Sci. 1999;  886 58-66
    PubMedGoogle Scholar
  • 50 Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel R S. Oncogenes as inducers of tumor angiogenesis.  Cancer Metast Rev. 1995;  14 263-277
    CrossrefPubMedGoogle Scholar
  • 51 Rak J, Mitsuhashi Y, Sheehan C et al.. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.  Cancer Res. 2000;  60 490-498
    PubMedGoogle Scholar
  • 52 Hanahan D, Weinberg R A. The hallmarks of cancer.  Cell. 2000;  100 57-70
    CrossrefPubMedGoogle Scholar
  • 53 Kieser A, Weich H A, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.  Oncogene. 1994;  9 963-969
    PubMedGoogle Scholar
  • 54 Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.  Cancer Res. 1996;  56 2299-2301
    PubMedGoogle Scholar
  • 55 Harada H, Nakagawa K, Iwata S et al.. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.  Cancer Res. 1999;  59 3783-3789
    PubMedGoogle Scholar
  • 56 Rak J, Yu J L, Klement G, Kerbel R S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth.  J Investig Dermatol Symp Proc. 2000;  5 24-33
    CrossrefPubMedGoogle Scholar
  • 57 Mazure N M, Chen E Y, Yeh P, Laderoute K R, Giaccia A J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression.  Cancer Res. 1996;  56 3436-3440
    PubMedGoogle Scholar
  • 58 Mazure N M, Chen E Y, Yeh P, Laderoute K R, Giaccia A J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element.  Blood. 1997;  90 3322-3331
    PubMedGoogle Scholar
  • 59 Laderoute K R, Alarcon R M, Brody M D et al.. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin-1 and the angiogenic inducer vascular endothelial growth factor.  Clin Cancer Res. 2000;  6 2941-2950
    PubMedGoogle Scholar
  • 60 Koura A N, Liu W, Kitadai Y, Singh R K, Radinsky R, Ellis L M. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density.  Cancer Res. 1996;  56 3891-3894
    PubMedGoogle Scholar
  • 61 Viloria-Petit A M, Rak J, Hung M-C, Rockwell P, Goldstein N, Kerbel R S. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.  Am J Pathol. 1997;  151 1523-1530
    PubMedGoogle Scholar
  • 62 Dvorak H F, Dvorak A M, Manseau E J, Wiberg L, Churchil W H. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression.  J Natl Cancer Inst. 1979;  62 1459-1472
    PubMedGoogle Scholar
  • 63 Ferrara N, Gerber H P, LeCounter J. The biology of VEGF and its receptors.  Nat Med. 2003;  9 669-676
    CrossrefPubMedGoogle Scholar
  • 64 Behzadian M A, Windsor L J, Ghaly N et al.. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor.  FASEB J. 2003;  17 752-754
    PubMedGoogle Scholar
  • 65 Francis J L, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy.  Semin Thromb Hemost. 1998;  24 93-109
    PubMedGoogle Scholar
  • 66 Callendar N S, Varki N, Rao L V. Immunohistochemical identification of tissue factor in solid tumors.  Cancer. 1992;  70 1194-1201
    PubMedGoogle Scholar
  • 67 Gordon S G. Cancer cell procoagulants and their role in malignant disease.  Semin Thromb Hemost. 1992;  18 424-433
    PubMedGoogle Scholar
  • 68 Cavanaugh P G, Sloane B F, Bajkowski A S, Taylor J D, Honn K V. Purification and characterization of platelet aggregating activity from tumor cells: copurification with procoagulant activity.  Thromb Res. 1985;  37 309-326
    CrossrefPubMedGoogle Scholar
  • 69 Chelladurai M, Honn K V, Walz D A. HLA-DR is a procoagulant.  Biochem Biophys Res Commun. 1991;  178 467-473
    CrossrefPubMedGoogle Scholar
  • 70 Rao L VM. Tissue factor as a tumor procoagulant.  Cancer Metastasis Rev. 1992;  11 249-266
    CrossrefPubMedGoogle Scholar
  • 71 Wojtukiewicz M Z, Zimnoch L, Kloczko J et al.. Heterogeneous expression of endothelial cell-associated proteins in gliomas of different malignancy. In: Messmer K, Kubler WM Proceedings of 6th World Congress for Microcirculation. Bologna, Italy; Monduzzi Editore 1996: 1007-1010
    Google Scholar
  • 72 Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, αvβ3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression.  Br J Cancer. 2000;  82 1967-1973
    CrossrefPubMedGoogle Scholar
  • 73 Wojtukiewicz M Z, Zacharski L R, Rucinska M et al.. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma.  Thromb Haemost. 1999;  82 1659-1662
    PubMedGoogle Scholar
  • 74 Abdulkadir S A, Carvalhal G F, Kaleem Z et al.. Tissue factor expression and angiogenesis in human prostate carcinoma.  Hum Pathol. 2000;  31 443-447
    CrossrefPubMedGoogle Scholar
  • 75 Wojtukiewicz M Z, Rucinska M, Zacharski R R et al.. Localization of blood coagulation factors in situ in pancreatic carcinoma.  Thromb Haemost. 2001;  86 1416-1420
    PubMedGoogle Scholar
  • 76 Zacharski L R, Wojtukiewicz M Z, Constantini V, Ornstein D L, Memoli V A. Pathways of coagulation/fibrinolysis activation in malignancy.  Semin Thromb Hemost. 1992;  18 104-116
    PubMedGoogle Scholar
  • 77 Zhang Y, Deng Y, Luther T et al.. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.  J Clin Invest. 1994;  94 1320-1327
    Google Scholar
  • 78 Contrino J, Hair G, Kreutzer D L, Rickles F R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease.  Nat Med. 1996;  2 209-215
    CrossrefPubMedGoogle Scholar
  • 79 Folkman J. Tumor angiogenesis and tissue factor.  Nat Med. 1996;  2 167-168
    PubMedGoogle Scholar
  • 80 Shoji M, Abe K, Nawroth P P, Rickles R. Molecular mechanisms linking thrombosis and angiogenesis in cancer.  Trends Cardiovasc Med. 1997;  7 52-59
    Google Scholar
  • 81 Shoji M, Hancock W W, Abe K et al.. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.  Am J Pathol. 1998;  152 399-411
    PubMedGoogle Scholar
  • 82 Abe K, Shoji M, Chen J et al.. Regulation of vascular endothelial growth production and angiogenesis by the cytoplasmic tail of tissue factor.  Proc Natl Acad Sci USA. 1999;  96 8663-8668
    Google Scholar
  • 83 Ollivier V, Bentolila S, Chabbat J, Hakim J, Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII.  Blood. 1998;  91 2698-2703
    PubMedGoogle Scholar
  • 84 Rottingen J A, Enden T, Camerer E, Iversen J G, Prydz H. Binding of human factor VIIa to tissue factor induces Ca2+ signals in J82 cells, transfected COS-1 cells, MDCK cells and in human endothelial cells induced to synthesize tissue factor.  J Biol Chem. 1995;  270 4650-4660
    CrossrefPubMedGoogle Scholar
  • 85 Camerer E, Rottingen J A, Iversen J G, Prydz H. Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active.  J Biol Chem. 1996;  271 29034-29042
    CrossrefPubMedGoogle Scholar
  • 86 Camerer E, Huang W, Coughlin S R. Tissue factor- and X-dependent activation of protease-activated receptor 2 by factor VIIa.  Proc Natl Acad Sci USA. 2000;  97 5255-5260
    CrossrefPubMedGoogle Scholar
  • 87 Prydz H, Camerer E, Rottingen J A, Wiiger M T, Gjernes E. Cellular consequences of the initiation of blood coagulation.  Thromb Haemost. 1999;  82 183-192
    PubMedGoogle Scholar
  • 88 Milanini J, Vinals F, Pouyssegur J, Pages G. p42/p44 MAP kinase model plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts.  J Biol Chem. 1998;  273 18165-18172
    CrossrefPubMedGoogle Scholar
  • 89 Poulsen L K, Jacobsen N, Sorensen B B et al.. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor.  J Biol Chem. 1998;  273 6228-6232
    CrossrefPubMedGoogle Scholar
  • 90 Sorensen B B, Freskgard P O, Nielsen L S, Rao L V, Ezban M, Peterson L C. Factor VIIa-induced p44/42 mitogen-activated protein activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain.  J Biol Chem. 1999;  274 21349-21354
    CrossrefPubMedGoogle Scholar
  • 91 Versteeg H H, Hoedemaeker I, Diks S H et al.. Factor VIIa/tissue factor-induced signaling via the activation of Src-like kinases, phosphatidyl inositol 3-kinase, and Rac.  J Biol Chem. 2000;  275 28750-28756
    CrossrefPubMedGoogle Scholar
  • 92 Ollivier V, Chabbat J, Herbert J M, Hakim J, de Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa.  Arterioscler Thromb Vasc Biol. 2000;  20 1374-1381
    PubMedGoogle Scholar
  • 93 Zioncheck T F, Roy S, Vehar G A. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism.  J Biol Chem. 1992;  267 3561-3564
    PubMedGoogle Scholar
  • 94 Yan S F, Zou Y S, Gao Y et al.. Tissue factor transcription driven by Egr-1 is critical mechanism of murine pulmonary fibrin deposition in hypoxia.  Proc Natl Acad Sci USA. 1998;  95 8298-8303
    CrossrefPubMedGoogle Scholar
  • 95 Yan S F, Lu J, Zou Y S et al.. Protein kinase C-beta and oxygen deprivation. A novel Egr-1-dependent pathway for fibrin deposition in hypoxemic vasculature.  J Biol Chem. 2000;  275 11921-11928
    CrossrefPubMedGoogle Scholar
  • 96 Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.  Nature. 1992;  359 843-845
    CrossrefPubMedGoogle Scholar
  • 97 Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor in vitro and in vivo.  Lab Invest. 1994;  71 374-379
    PubMedGoogle Scholar
  • 98 Goldberg M A, Schneider T J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.  J Biol Chem. 1994;  269 4355-4359
    PubMedGoogle Scholar
  • 99 Amirkhosravi A, Meyer T, Warnes G et al.. Pentoxyfilline inhibits hypoxia-induced up-regulation of tumor cell tissue factor and vascular endothelial growth factor.  Thromb Haemost. 1998;  80 598-602
    PubMedGoogle Scholar
  • 100 O'Rourke J, Pugh C, Bartlett S, Ratcliffe P. Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1.  Eur J Biochem. 1996;  241 403-410
    CrossrefPubMedGoogle Scholar
  • 101 Mechtcheriakova D, Wlachos A, Holzmüller H, Binder B R, Hofer E. Vascular endothelial growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1.  Blood. 1999;  93 3811-3823
    PubMedGoogle Scholar
  • 102 Wojtukiewicz M Z, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy.  Neoplasia. 2001;  3 371-384
    Google Scholar
  • 103 Rak J, Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer.  Cancer Metastasis Rev. 2000;  19 93-96
    CrossrefPubMedGoogle Scholar
  • 104 Bromberg M E, Cappello M. Cancer and blood coagulation: molecular aspects.  Cancer J Sci Am. 1999;  5 132-138
    PubMedGoogle Scholar
  • 105 Bajaj M S, Bajaj S P. Tissue factor pathway inhibitor: potential therapeutic applications.  Thromb Haemost. 1997;  78 471-477
    PubMedGoogle Scholar
  • 106 Sevinsky J R, Rao L VM, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.  J Cell Biol. 1996;  133 293-304
    Google Scholar
  • 107 Werling R W, Zacharski L R, Kisiel W, Bajaj S P, Memoli V A, Rousseau S A. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.  Thromb Haemost. 1993;  69 366-369
    Google Scholar
  • 108 Mousa S A, Mohamed S. Anti-angiogenesis efficacy of the low molecular weight heparin (LMWH) tinzaparin and tissue factor pathway inhibitor (TFPI) [abstract].  Blood. 1999;  94(suppl) A22,82
    PubMedGoogle Scholar
  • 109 Amirkhosravi A, Francis J, Mousa S A. Anti-metastatic effect of the low molecular weight heparin (LMWH) tinzaparin and tissue factor pathway inhibitor (TFPI) [abstract].  Thromb Haemost. 2001;  15(suppl) A118,149
    PubMedGoogle Scholar
  • 110 Ruf W, Mueller B M. Tissue factor in cancer angiogenesis and metastasis.  Curr Opin Hematol. 1996;  3 379-384
    CrossrefPubMedGoogle Scholar
  • 111 Ruf W, Mueller B M. Tissue factor signalling.  Thromb Haemost. 1999;  82 175-182
    PubMedGoogle Scholar
  • 112 Sprecher C A, Kisiel W, Mathews S M, Foster D C. Molecular cloning, expression, and partial characterization of a second tissue-factor-pathway-inhibitor.  Proc Natl Acad Sci USA. 1994;  91 3353-3357
    Google Scholar
  • 113 Peterson L C, Sprecher C A, Foster D C, Blumberg H, HamamotoT, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.  Biochemistry. 1996;  35 266-272
    Google Scholar
  • 114 Iino M, Foster D C, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2.  Arterioscler Thromb Vasc Biol. 1998;  18 40-46
    PubMedGoogle Scholar
  • 115 Rao C N, Cook B, Liu Y et al.. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.  Int J Cancer. 1998;  76 749-756
    Google Scholar
  • 116 Rao C N, Mohanam S, Puppala A, Rao J S. Regulation of pro-MMP-1 and pro-MMP-3 activation by tissue factor pathway inhibitor-2/matrix associated serine protease inhibitor.  Biochem Biophys Res Commun. 1999;  255 94-98
    CrossrefPubMedGoogle Scholar
  • 117 Wojtukiewicz M Z, Sierko E, Zimnoch L, Kozlowski L, Kisiel W. Immunochistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue.  Thromb Haemost. 2003;  90 140-146
    PubMedGoogle Scholar
  • 118 Wojtukiewicz M Z, Tang D G, Nelson K K, Walz D A, Diglio C A, Honn K V. Thrombin enhances tumor cell adhesive and metastatic properties via increased αIIbβ3 expression on the cell surface.  Thromb Res. 1992;  68 233-245
    CrossrefPubMedGoogle Scholar
  • 119 Wojtukiewicz M Z, Tang D G, Ben-Josef E, Renaud C, Walz D A, Honn K V. Solid tumor cells express functional “tethered-ligand” thrombin receptor.  Cancer Res. 1995;  55 698-704
    PubMedGoogle Scholar
  • 120 Zhou H, Gabazza E C, Takeya H et al.. Prothrombin and its derivatives stimulate motility of melanoma cells.  Thromb Haemost. 1998;  80 407-412
    PubMedGoogle Scholar
  • 121 Wojtukiewicz M Z, Tang D G, Ciarelli J J et al.. Thrombin increases the metastatic potential of tumor cells.  Int J Cancer. 1993;  54 793-806
    CrossrefPubMedGoogle Scholar
  • 122 Fischer E G, Ruf W, Mueller B M. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.  Cancer Res. 1995;  55 1629-1632
    PubMedGoogle Scholar
  • 123 Tsopanoglou N E, Pipili-Synetos E, Maragoudakis M E. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation.  Am J Physiol. 1993;  264 C1302-1307
    PubMedGoogle Scholar
  • 124 Zacharski L R, Costantini V, Wojtukiewicz M Z, Memoli V A, Kudryk B J. Anticoagulants as cancer therapy.  Semin Oncol. 1990;  17 217-227
    PubMedGoogle Scholar
  • 125 Gaffney P J, Edgell T A, Whitton C M. The hemostatic balance-Astrup revised.  Haemostasis. 1999;  29 58-71
    CrossrefPubMedGoogle Scholar
  • 126 Ukropec J A, Hollinger M K, Salva S M, Woolkalis M J. SHP2 assoctiation with VE-cadherin complexes in human endothelial cells is regulated by thrombin.  J Biol Chem. 2000;  275 5983-5986
    CrossrefPubMedGoogle Scholar
  • 127 Maragoudakis M E, Tsopanoglou N E, Andriopoulou P, Maragoudakis M M. Effects of thrombin/thrombosis in angiogenesis and tumor progression.  Matrix Biol. 2000;  19 345-351
    CrossrefPubMedGoogle Scholar
  • 128 Belloni P A, Carney D H, Nicolson G L. Organ-derived microvessel endothelial cells exhibit differential responsiveness to thrombin and other growth factors.  Microvasc Res. 1992;  43 20-45
    PubMedGoogle Scholar
  • 129 Naldini A, Carney D H, Pucci A, Pasquall A, Carraro F. Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1.  Gen Pharmacol. 2000;  35 255-259
    CrossrefPubMedGoogle Scholar
  • 130 Herbert J M, Dupuy E, Laplace M C, Zini J M, Shavit R B, Tobelem G. Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway.  Biochem J. 1994;  303 227-231
    PubMedGoogle Scholar
  • 131 Tsopanoglou N E, Maragoudakis M E. On the mechanism of thrombin-induced angiogenesis.  J Biol Chem. 1999;  274 23969-23976
    CrossrefPubMedGoogle Scholar
  • 132 Yamahata H, Takeshima H, Kuratsu J et al.. The role of thrombin in the neo-vascularisation of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor.  Int J Oncol. 2002;  20 921-928
    PubMedGoogle Scholar
  • 133 Möhle R, Green D, Moore M AS, Nachman R L, Rafh S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.  Proc Natl Acad Sci USA. 1997;  94 663-668
    CrossrefPubMedGoogle Scholar
  • 134 Benezra M, Vlodavsky I, Ishai-Michaeli R, Neufeld G, Bar-Shavit R. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix.  Blood. 1993;  81 3324-3331
    PubMedGoogle Scholar
  • 135 Huang Y Q, Li J J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells.  Blood. 2002;  99 1646-1650
    CrossrefPubMedGoogle Scholar
  • 136 Hanahan D. Signalling vascular morphogenesis and maintenance.  Science. 1997;  277 48-50
    CrossrefPubMedGoogle Scholar
  • 137 Levin E G, Stern D M, Nawroth P P et al.. Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells.  Thromb Haemost. 1986;  56 115-119
    PubMedGoogle Scholar
  • 138 Zucker S, Conner C, DiMassmo B I et al.. Thrombin induces the activation of progelatinase A in vascular endothelial cells.  J Biol Chem. 1995;  270 23730-23738
    CrossrefPubMedGoogle Scholar
  • 139 Good D J, Polverini P J, Rastinejad F et al.. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.  Proc Natl Acad Sci USA. 1990;  87 6624-6628
    PubMedGoogle Scholar
  • 140 Lee T H, Rhim T H, Kim S S. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells.  J Biol Chem. 1998;  273 28805-28812
    CrossrefPubMedGoogle Scholar
  • 141 Rhim T H, Park C S, Kim E, Kim S S. Human prothrombin fragment 1 + 2 inhibit bFGF-induced BCE cell growth.  Biochem Biophys Res Commun. 1998;  252 513-516
    CrossrefPubMedGoogle Scholar
  • 142 Prox D, Becker C, Pirie-Shepherd S, Celik I, Folkman J, Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors.  World J Surg. 2003;  27 405-411
    CrossrefPubMedGoogle Scholar
  • 143 Kisker O, Onizuka S, Banyard J et al.. Generation of multiple angiogenesis inhibitors by human pancreatic cancer.  Cancer Res. 2001;  61 7298-7304
    PubMedGoogle Scholar
  • 144 Larsson H, Sjoblom T, Dixelius J et al.. Antiangiogenic effects of latent antithrombin through perturbated cell-matrix interactions and apoptosis of endothelial cells.  Cancer Res. 2000;  60 6723-6729
    PubMedGoogle Scholar
  • 145 Larsson H, Akerud P, Nordling K, Rauh-Segall E, Claesson-Welsh L, Bjork I. A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity.  J Biol Chem. 2001;  276 11996-12002
    CrossrefPubMedGoogle Scholar
  • 146 Pahl M V, Vaziri N D, Oveisi F, Wang J, Ding Y. Antithrombin III inhibits mesangial cell proliferation.  J Am Soc Nephrol. 1996;  7 2249-2253
    PubMedGoogle Scholar
  • 147 Souter P J, Thomas S, Hubbard A R, Poole S, Römisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood.  Crit Care Med. 2001;  29 134-139
    PubMedGoogle Scholar
  • 148 Bombeli T, Mueller M, Haeberii A. Anticoagulant properties of the vascular endothelium.  Thromb Haemost. 1997;  77 408-423
    Article in Thieme ConnectPubMedGoogle Scholar
  • 149 Calnek D S, Grinnell B W. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor.  Exp Cell Res. 1998;  238 294-298
    CrossrefPubMedGoogle Scholar
  • 150 Nguyen M, Arkell J, Jackson C J. Activated protein C activates human endothelial gelatinase A.  J Biol Chem. 2000;  275 9095-9098
    CrossrefPubMedGoogle Scholar
  • 151 Yoda Y, Abe T. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease.  Thromb Haemost. 1981;  46 706-709
    PubMedGoogle Scholar
  • 152 Dvorak H F, Brown L F, Detmar M, Dvorak A M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.  Am J Pathol. 1995;  146 1029-1039
    PubMedGoogle Scholar
  • 153 Cheresh D A, Berliner S A, Vicente V, Ruggeri Z M. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells.  Cell. 1989;  58 945-953
    CrossrefPubMedGoogle Scholar
  • 154 Thiagarajan P, Rippon A J, Farrel D H. Alternative sites in human fibrinogen for vascular endothelial cells.  Biochemistry. 1996;  35 4169-4175
    CrossrefPubMedGoogle Scholar
  • 155 Dallabrida S M, Falls L A, Farrell D H. Factor XIIIa supports microvascular endothelial cell adhesion and inhibits capillary tube formation in fibrin.  Blood. 2000;  95 2586-2592
    PubMedGoogle Scholar
  • 156 Hynes R O. Integrins: bi-directional, allosteric signaling machines.  Cell. 2002;  110 673-687
    CrossrefPubMedGoogle Scholar
  • 157 Sahni A, Odrljin T, Francis C W. Binding of basic fibroblast growth factor to fibrinogen and fibrin.  J Biol Chem. 1998;  273 7554-7559
    CrossrefPubMedGoogle Scholar
  • 158 Sahni A, Baker C A, Sporn L A, Francis C W. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation.  Thromb Haemost. 2000;  83 736-741
    PubMedGoogle Scholar
  • 159 Sahni A, Francis C W. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation.  Blood. 2000;  96 3772-3778
    PubMedGoogle Scholar
  • 160 Sahni A, Sporn L A, Francis C W. Potentiation of endothelial cell proliferation by fibrin (ogen)-bound fibroblast growth factor-2.  J Biol Chem. 1999;  274 14936-14941
    CrossrefPubMedGoogle Scholar
  • 161 Contrino J, Goralnick S, Qi J, Hair G, Rickles F R, Kreutzer D L. Fibrin induction of tissue factor expression in human vascular endothelial cells.  Circulation. 1997;  96 605-613
    PubMedGoogle Scholar
  • 162 Qi J, Kreutzer D L. Fibrin activation of endothelial cells: induction of IL-8 expression.  J Immunol. 1995;  155 867-876
    PubMedGoogle Scholar
  • 163 Thompson W D, Smith E B, Stirk C M, Marshall F I, Stout A J, Kocchar A. Angiogenic activity of fibrin degradation products is located in fibrin fragment E.  J Pathol. 1992;  168 47-53
    PubMedGoogle Scholar
  • 164 Bootle-Wilbraham C A, Tazzyman S, Thompson W D, Stirk C M, Lewis C E. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro.  Angiogenesis. 2001;  4 269-275
    CrossrefPubMedGoogle Scholar
  • 165 Bootle-Wilbraham C A, Tazzyman S, Marshal J M, Lewis C E. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro.  Cancer Res. 2000;  60 4719-4724
    PubMedGoogle Scholar
  • 166 Sporn L, Bunce L A, Francis C W. Cell proliferation on fibrin: modulation by fibrinopeptide cleavage.  Blood. 1995;  86 1802-1810
    PubMedGoogle Scholar
  • 167 Bunce L A, Sporn L A, Francis C W. Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the β chain.  J Clin Invest. 1992;  89 842-850
    PubMedGoogle Scholar
  • 168 Palumbo J S, Kombrinck K W, Drew A F et al.. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.  Blood. 2000;  96 3302-3309
    Google Scholar
  • 169 Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis.  J Biol Chem. 2000;  275 1521-1524
    CrossrefPubMedGoogle Scholar
  • 170 Foekens J A, Peters H A, Look M P et al.. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.  Cancer Res. 2000;  60 636-643
    PubMedGoogle Scholar
  • 171 Okusa Y, Ichikura T, Mochizuki H. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.  Cancer. 1999;  85 1033-1038
    CrossrefPubMedGoogle Scholar
  • 172 Harvey S R, Sait S NJ, Xu Y, Bailey J L, Penetrante R M, Markus G. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.  Am J Pathol. 1999;  155 1115-1120
    PubMedGoogle Scholar
  • 173 Oka T, Ishida T, Nishino T, Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.  Cancer Res. 1991;  51 274-281
    PubMedGoogle Scholar
  • 174 Evans C P, Elfman F, Parangi S, Conn M, Cuhna G, Shuman M A. Inhibition of prostate cancer neovascularisation and growth by urokinase-plasminogen activator receptor blockade.  Cancer Res. 1997;  57 3594-3599
    PubMedGoogle Scholar
  • 175 Kuhn W, Schmalfeld B, Reuning U et al.. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.  Br J Cancer. 1999;  79 1746-1751
    CrossrefPubMedGoogle Scholar
  • 176 deWitte J H, Sweep C GJ, Klijn J GM et al.. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.  Br J Cancer. 1999;  80 286-294
    CrossrefPubMedGoogle Scholar
  • 177 Franks A J, Ellis E. Immunohistochemical localization of tissue plasminogen activator in human brain tumors.  Br J Cancer. 1989;  59 462-466
    PubMedGoogle Scholar
  • 178 Bajou K, Noel A, Gerard R D et al.. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularisation.  Nat Med. 1998;  4 923-927
    CrossrefPubMedGoogle Scholar
  • 179 Mandriota S J, Seghezzi G, Vassalli J D et al.. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells.  J Biol Chem. 1995;  270 9709-9716
    CrossrefPubMedGoogle Scholar
  • 180 Pepper M S, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells.  Biochem Biophys Res Commun. 1991;  181 902-906
    CrossrefPubMedGoogle Scholar
  • 181 Gualandris A, Presta M. Transcriptional and posttranscriptional regulation of urokinase-type plasminogen activator expression in endothelial cells by basic fibroblast growth factor.  J Cell Physiol. 1995;  162 400-409
    CrossrefPubMedGoogle Scholar
  • 182 Mignatti P, Mazzieri R, Rifkin D B. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor.  J Cell Biol. 1991;  113 1193-1201
    CrossrefPubMedGoogle Scholar
  • 183 Bikfalvi A, Klein S, Pintucci G, Rifkin D B. Biological roles of fibroblast growth factor-2.  Endocrinol Rev. 1997;  18 26-45
    CrossrefPubMedGoogle Scholar
  • 184 Pepper M S, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro.  Biochem Biophys Res Commun. 1992;  189 824-831
    CrossrefPubMedGoogle Scholar
  • 185 Asahara T, Bauters C, Zheng L P et al.. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo.  Circulation. 1995;  92(suppl II) II365-II371
    PubMedGoogle Scholar
  • 186 Pepper M S, Mandriota S J. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells.  Exp Cell Res. 1998;  241 414-425
    CrossrefPubMedGoogle Scholar
  • 187 Lindgren M, Johansson M, Sandstrom J, Jonsson Y, Bergenheim A T, Henricsson R. VEGF and tPA co-expressed in malignant glioma.  Acta Oncol. 1997;  36 615-623
    PubMedGoogle Scholar
  • 188 Sandström M, Johansson M, Sandström J, Bergenheim A T, Henriksson R. Expression of the proteolytic factors tPA and uPA, PAI-1 and VEGF during malignant glioma progression.  Int J Dev Neurosci. 1999;  17 473-481
    PubMedGoogle Scholar
  • 189 Nakata S, Ito K, Fujimori M et al.. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancer.  Int J Cancer. 1998;  79 179-186
    CrossrefPubMedGoogle Scholar
  • 190 Naldini L, Tamagnone L, Vigna E et al.. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.  EMBO J. 1992;  11 4825-4833
    PubMedGoogle Scholar
  • 191 Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin D B. Characterization of the activation of latent TGF-beta by co-cultures of pericytes and smooth muscle cells: a self regulating system.  J Cell Biol. 1990;  111 757-763
    CrossrefPubMedGoogle Scholar
  • 192 Gille J, Khalik M, Konig V, Kaufmann R. Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes.  J Invest Dermatol. 1998;  111 1160-1165
    CrossrefPubMedGoogle Scholar
  • 193 Yamane A, Seetharam L, Yamguchi S et al.. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase family (Flt-1 and KDR/Flk-1).  Oncogene. 1994;  9 2683-2690
    PubMedGoogle Scholar
  • 194 Pepper M S. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity.  Cytokine Growth Factor Rev. 1997;  8 21-43
    CrossrefPubMedGoogle Scholar
  • 195 Antonelli-Orlidge A, Saunders K B, Smith S R, D'Amore P A. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes.  Proc Natl Acad Sci USA. 1989;  86 4544-4548
    PubMedGoogle Scholar
  • 196 Carmeliet P. Mechanisms of angiogenesis and arteriogenesis.  Nat Med. 2000;  6 389-395
    CrossrefPubMedGoogle Scholar
  • 197 Petrovaara L, Kaipanen A, Mustonen T et al.. Vascular endothelial growth factor is induced in response to transforming growth factor beta in fibroblastic and epithelial cells.  J Biol Chem. 1994;  269 6271-6274
    PubMedGoogle Scholar
  • 198 O'Mahony C A, Albo D, Tuszynsky G P, Berger D H. Transforming growth factor-beta-1 inhibits generation of angiostatin by human pancreatic cancer cells.  Surgery. 1998;  124 388-393
    CrossrefPubMedGoogle Scholar
  • 199 Fukao H, Ueshima S, Okada K, Matsuo O. The role of pericellular fibrinolytic system in angiogenesis.  Jpn J Physiol. 1997;  47 161-171
    CrossrefPubMedGoogle Scholar
  • 200 Hiroaka N, Allen E, Apel I J, Gyetko M R, Weiss S J. Matrix metalloproteinases regulate neovascularisation by acting as pericellular fibrinolysins.  Cell. 1998;  95 365-377
    CrossrefPubMedGoogle Scholar
  • 201 Carmeliet P, Moons L, Dewerchin M et al.. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and plasminogen system.  Ann N Y Acad Sci. 1997;  811 191-206
    PubMedGoogle Scholar
  • 202 Heymans S, Luttun A, Nuyens D et al.. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.  Nat Med. 1999;  5 1135-1142
    CrossrefPubMedGoogle Scholar
  • 203 Schleef R R, Loskutoff D J. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors.  Haemostasis. 1988;  18 328-341
    PubMedGoogle Scholar
  • 204 Kroon M E, Koolwijk P, van Goor H et al.. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices.  Am J Pathol. 1999;  154 1731-1742
    PubMedGoogle Scholar
  • 205 Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system.  Thromb Haemost. 1999;  82 298-304
    PubMedGoogle Scholar
  • 206 Ossowski L, Clunine G, Masucci M T, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.  J Cell Biol. 1991;  115 1107-1112
    CrossrefPubMedGoogle Scholar
  • 207 Koshelnick Y, Ehart M, Stockinger H, Binder B R. Mechanisms of signaling through urokinase receptor and the cellular response.  Thromb Haemost. 1999;  82 305-311
    PubMedGoogle Scholar
  • 208 Colman R W, Pixley R A, Najamunnisa S et al.. Binding of high molecular weight kininogen to endothelial cells via a site within domains 2 and 3 of the urokinase receptor.  J Clin Invest. 1997;  100 1481-1487
    CrossrefPubMedGoogle Scholar
  • 209 Colman R W, Jameson B A, Lin Y, Johnson D, Mousa S A. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis.  Blood. 2000;  95 543-550
    PubMedGoogle Scholar
  • 210 Peek M, Moran P, Mendoza N, Wickramasinghe D, Kirchhofer D. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.  J Biol Chem. 2002;  277 47804-47809
    CrossrefPubMedGoogle Scholar
  • 211 Deng G, Curriden S A, Wang S, Rosenberg S, Loskutoff D J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?.  J Cell Biol. 1996;  134 1-9
    CrossrefPubMedGoogle Scholar
  • 212 Minor K H, Peterson C B. Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix.  J Biol Chem. 2002;  277 10337-10345
    CrossrefPubMedGoogle Scholar
  • 213 McMahon G A, Petitclerc E, Stefansson S et al.. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.  J Biol Chem. 2001;  276 33964-33968
    CrossrefPubMedGoogle Scholar
  • 214 O'Reilly M S, Holmgreen L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice.  Nat Med. 1996;  2 689-692
    PubMedGoogle Scholar
  • 215 Soff G A, Hong J, Fishman D et al.. Angiostatin 4.5: a naturally occurring human angiogenesis inhibitor [abstract].  Blood. 1998;  92(suppl) 174A
    PubMedGoogle Scholar
  • 216 Cao R, Wu H L, Veitonmaki N et al.. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis.  Proc Natl Acad Sci USA. 1999;  96 5728-5733
    CrossrefPubMedGoogle Scholar
  • 217 Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer.  Haematologica. 1999;  84 643-650
    PubMedGoogle Scholar
  • 218 Olas B, Mielicki W P, Wachowicz B, Krajewski T. Cancer procoagulant stimulates platelets adhesion.  Thromb Res. 1999;  94 199-203
    CrossrefPubMedGoogle Scholar
  • 219 Banks R E, Forbes M A, Kinsey S E et al.. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.  Br J Cancer. 1998;  77 956-964
    CrossrefPubMedGoogle Scholar
  • 220 Honn K V, Tang G T, Chen Y Q. Platelets and cancer metastasis: more than an epiphenomenon.  Semin Thromb Hemost. 1992;  18 392-415
    PubMedGoogle Scholar
  • 221 Verheul H M, Jorna A S, Hoekman K et al.. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets.  Blood. 2000;  96 4216-4221
    PubMedGoogle Scholar
  • 222 Clauss M, Gerlach M, Gerlach H et al.. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.  J Exp Med. 1990;  172 1535-1545
    CrossrefPubMedGoogle Scholar
  • 223 Verheul H MW, Hoekman K, Luykx-de Bakker S et al.. Platelet: transporter of vascular endothelial growth factor.  Clin Cancer Res. 1997;  3 2187-2190
    PubMedGoogle Scholar
  • 224 Wartiovaara U, Salven P, Mikkola Heta I. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.  Thromb Haemost. 1998;  80 171-175
    PubMedGoogle Scholar
  • 225 Brunner G, Nguyen H, Gabrilove J et al.. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells.  Blood. 1993;  81 631-638
    PubMedGoogle Scholar
  • 226 Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary culture.  Proc Natl Acad Sci USA. 1986;  83 6489-6493
    PubMedGoogle Scholar
  • 227 Karey K P, Marquardt H, Sirbasku D A. Human platelet-derived mitogens. I. Identification of insulin-like growth factors I and II by purification and N-terminal amino acid sequence analysis.  Blood. 1989;  74 1084-1092
    PubMedGoogle Scholar
  • 228 Karey K P, Sirbasku D A. Human platelets-derived mitogens. II. Subcellular localization of insulin-like growth factor I to the alpha granule and release in response to thrombin.  Blood. 1989;  74 1093-1100
    CrossrefPubMedGoogle Scholar
  • 229 Ben-Ezra J, Sheibani K, Hwang D L, Lev-Ran A. Megakaryocyte synthesis is the source of epidermal growth factor in human platelets.  Am J Pathol. 1990;  137 755-759
    PubMedGoogle Scholar
  • 230 Griffiths L, Stratford I J. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy.  Br J Cancer. 1997;  76 689-693
    PubMedGoogle Scholar
  • 231 Betsholtz C, Karlson L, Lindahl P. Developmental roles of platelet-derived growth factors.  Bioessays. 2001;  23 494-507
    CrossrefPubMedGoogle Scholar
  • 232 Ceni E, Granchi D, Vancini M, Pizzoferrato A. Platelet release of transforming growth factor-beta and beta-thromboglobulin after in vitro contact with acrylic bone cements.  Biomaterials. 2002;  23 1479-1484
    CrossrefPubMedGoogle Scholar
  • 233 Li J J, Huang Y Q, Basch R, Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets.  Thromb Haemost. 2001;  85 204-206
    PubMedGoogle Scholar
  • 234 Good D J, Polverini P J, Rastinejad F et al.. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.  Proc Natl Acad Sci USA. 1990;  87 6624-6628
    PubMedGoogle Scholar
  • 235 Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis.  Nature. 1982;  297 307-312
    CrossrefPubMedGoogle Scholar
  • 236 Ma L, Hollenberg M D, Wallace J L. Thrombin-induced platelet endostatin release is blocked by a protamine activated receptor-4 (PAR-4) antagonist.  Br J Pharmacol. 2001;  134 701-704
    CrossrefPubMedGoogle Scholar
  • 237 Yokoyama Y, Charnock-Jones D S, Licence D et al.. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.  Clin Cancer Res. 2003;  9 1361-1369
    PubMedGoogle Scholar
  • 238 Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production.  Br J Pharmacol. 2003;  139 329-336
    CrossrefPubMedGoogle Scholar
  • 239 Stoeltzing O, Ahmad S A, Liu W et al.. Angiopoietin-1 inhibits tumor growth and ascites formation in a murine model of peritoneal carcinomatosis.  Br J Cancer. 2002;  87 1182-1187
    CrossrefPubMedGoogle Scholar
  • 240 Selheim F, Fukami M H, Holmsen H, Vassbotn F S. Platelet-derived-growth-factor-induced signaling in human platelets: phosphoinositide-3-kinase-dependent inhibition of platelet activation.  Biochem J. 2000;  350 469-475
    CrossrefPubMedGoogle Scholar
  • 241 Selheim F, Holmsen H, Vassbotn F S. Identification of functional VEGF receptors on human platelets.  FEBS Lett. 2002;  512 107-110
    CrossrefPubMedGoogle Scholar
  • 242 Tsiamis A C, Hayes P, Box H et al.. Characterization and regulation of the receptor tyrosine kinase Tie-1 in platelets.  J Vasc Res. 2000;  37 437-442
    CrossrefPubMedGoogle Scholar
  • 243 Carmeliet P. Biomedicine. Clotting factors build blood vessels.  Science. 2001;  31 1602-1604
    PubMedGoogle Scholar
  • 244 Kalluri R. Angiogenesis: basement membranes: structure, assembly and role in tumor angiogenesis.  Nat Rev Cancer. 2003;  3 422-433
    CrossrefPubMedGoogle Scholar
  • 245 Kuenan B C, Levi M, Meijers J C et al.. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and angiogenesis inhibitor SU 5416.  J Clin Oncol. 2003;  21 2192-2198
    CrossrefPubMedGoogle Scholar

Marek Z WojtukiewiczM.D. 

Department of Oncology, Medical University

12 Ogrodowa St, 15-027 Bialystok, Poland

Email: mwojtuk@polbox.com

      >